First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.

Key Points: Question: What are the long-term efficacy and safety outcomes of adding serplulimab to first-line chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC)? Findings: In this secondary analysis of an international, double-blind, phase 3 randomized clinical tr...

Descripción completa

Detalles Bibliográficos

Publicado en:	JAMA Oncology Vol. 12; no. 8; pp. 810 - 819
Autores principales:	Liu, Jingjing, Han, Liang, Wu, Lin, Chen, Jun, Sun, Hongmei, Wen, Guilan, Ji, Yinghua, Shi, Jianhua, Pan, Zhijie, Shi, Jinsheng, Wang, Xicheng, Bai, Yuansong, Pan, Yueyin, Min, Xuhong, Viguro, Maksym, Li, Xingya, Zhao, Yanqiu, Yang, Junquan, Makharadze, Tamta, Arkania, Ekaterine
Formato:	research tables/charts Journal Article
Publicado:	American Medical Association Aug2026
Acceso en línea:	Ver este registro en EBSCOhost